Head CT for prognostication
Brain injury is a leading cause of death among patients who are hospitalised after cardiac arrest (CA). A large majority of these patients die following withdrawal of life sustaining therapy (WLST) due to poor neurological prognosis. A multimodal prognostication approach may be needed so that the results of a clinical neurological examination can be considered together with the findings of electrophysiological investigations, serum biomarkers and neuroimaging.
Findings from a large European survey show that head computed tomography (CT) and EEG are the two most frequently used methods for prognostication. CT offers several benefits. It is widely available and is also cheaper and easier to perform on ICU patients when compared to MRI. CT is commonly performed to rule out non-cardiac causes of arrest. Soon after a cerebral ischaemia, energy depletion can lead to cytotoxic oedema. Neuron-specific enolase (NSE) is a marker of neuronal damage and is recommended for prognostication after CA.
During the Targeted Temperature Management After Out-of-Hospital Cardiac Arrest Trial (TTM-trial), researchers described CT findings after CA and also investigated whether generalised oedema alone or in combination with peak-NSE predicted poor outcome. The researchers also investigated the relationship of serum NSE levels to cerebral oedema on head CT.
Neurological outcome was determined at a follow-up approximately 6 months after the cardiac arrest. The Cerebral Performance Category Scale (CPC) was used. Outcome was defined as good cerebral performance (CPC 1); moderate cerebral disability (CPC 2); severe disability (CPC 3); vegetative state (CPC 4); and brain death (CPC 5).
CT examinations in half of the study patients were performed within 24 hours after CA. 79.8% of these were normal and 9.6% were with generalised oedema.
Cerebral oedema was diagnosed in 45.5% of CT examinations performed 24h-7d post-arrest. These patients often had a poor neurological outcome as compared to patients with CT performed before 24h. Within 24h after cardiac arrest, generalised oedema predicted poor outcome with 14.4% sensitivity and 97.6% specificity. In cases where early CT did not show oedema, 58% patients still had poor outcome at 6 months. Generalised oedema on head-CT 24h-7d post-arrest showed 56.5% sensitivity and 100% specificity for predicting poor outcome.
Study researchers also observed that the combination of head CT and peak-NSE improved sensitivity to predict poor outcome as compared to early CT alone.
Overall, the researchers conclude that findings of generalised oedema on non-contrast enhanced head computed tomography, assessed by a local radiologist, is a reliable predictor of poor outcome after cardiac arrest. The presence of genealised oedema can be of great value to guide treatment decisions as well as give early information about expected prognosis. In addition, the combination of head CT with serum NSE-levels further increased the prognostic performance thus providing evidence in favour of multi-modal algorithms.
Image Credit: JBER
Published on : Thu, 14 Sep 2017
Print as PDF
The iLA Membrane Ventilator is an extrapulmonary ventilation system which is used primarily to remove carbon dioxide. The heart pumps blood through it as it does through a natural organ. The gas exchange takes place via a plasma-tight, heparin-coated...
Features The SynoVent E3 does not only include advanced ventilator functionality but also a modern, easy to use interface. The display can be configured to suit each clinician’s taste and needs, and gives quick and easy control over ventilator parameters...
FeaturesSV 300 is a state-of-the-art ventilator that’s simple to configure, easy to operate and versatile in use. It equips with extensive ventilation modes that can treats pediatric and adult patients with all acuity levels at ICUs and Intermediate Care.With...
XENIOS AG is a medical device company with the three brands, novalung, i-cor and medos, that run on a single XENIOS platform. This platform enables next-generation therapies for lung and heart failure. No other company except XENIOS AG is offering lung...
The HAMILTON-C1 neo is a versatile neonatal ventilator that combines invasive and noninvasive modes with the additional options of nCPAP and high flow oxygen therapy. The integrated turbine allows it to be operated independently of a compressed air supply....